Atossa Genetics Inc (ATOS) - Net Assets
Based on the latest financial reports, Atossa Genetics Inc (ATOS) has net assets worth $49.79 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($58.01 Million) and total liabilities ($8.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATOS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $49.79 Million |
| % of Total Assets | 85.82% |
| Annual Growth Rate | 67.32% |
| 5-Year Change | 163.09% |
| 10-Year Change | 1810.26% |
| Growth Volatility | 745.94 |
Atossa Genetics Inc - Net Assets Trend (2009–2024)
This chart illustrates how Atossa Genetics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Atossa Genetics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Atossa Genetics Inc (2009–2024)
The table below shows the annual net assets of Atossa Genetics Inc from 2009 to 2024. For live valuation and market cap data, see ATOS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $71.48 Million | -21.47% |
| 2023-12-31 | $91.02 Million | -22.84% |
| 2022-12-31 | $117.96 Million | -14.60% |
| 2021-12-31 | $138.14 Million | +408.45% |
| 2020-12-31 | $27.17 Million | +106.51% |
| 2019-12-31 | $13.16 Million | +49.41% |
| 2018-12-31 | $8.81 Million | +26.90% |
| 2017-12-31 | $6.94 Million | +124.04% |
| 2016-12-31 | $3.10 Million | -17.23% |
| 2015-12-31 | $3.74 Million | -60.61% |
| 2014-12-31 | $9.50 Million | -10.41% |
| 2013-12-31 | $10.60 Million | +104.84% |
| 2012-12-31 | $5.18 Million | +231.82% |
| 2011-12-31 | $1.56 Million | +283.10% |
| 2010-12-31 | $-851.85K | -2788.67% |
| 2009-12-31 | $31.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Atossa Genetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21166914300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.49 Million | 32.86% |
| Other Components | $259.78 Million | 363.45% |
| Total Equity | $71.48 Million | 100.00% |
Atossa Genetics Inc Competitors by Market Cap
The table below lists competitors of Atossa Genetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Choice Development Inc
TW:9929
|
$35.74 Million |
|
Candles Scandinavia AB Series B
ST:CANDLE-B
|
$35.74 Million |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
$35.75 Million |
|
Megastar Foods Limited
NSE:MEGASTAR
|
$35.76 Million |
|
Seresco S.A.
MC:SCO
|
$35.73 Million |
|
VerticalScope Holdings Inc
TO:FORA
|
$35.70 Million |
|
Singulus Technologies AG
XETRA:SNG
|
$35.68 Million |
|
S P V I Public Company Limited
BK:SPVI
|
$35.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atossa Genetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 91,016,000 to 71,477,000, a change of -19,539,000 (-21.5%).
- Net loss of 25,504,000 reduced equity.
- Other factors increased equity by 5,965,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.50 Million | -35.68% |
| Other Changes | $5.96 Million | +8.35% |
| Total Change | $- | -21.47% |
Book Value vs Market Value Analysis
This analysis compares Atossa Genetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $9.36 | $5.33 | x |
| 2010-12-31 | $-383.03 | $5.33 | x |
| 2011-12-31 | $461.87 | $5.33 | x |
| 2012-12-31 | $1122.19 | $5.33 | x |
| 2013-12-31 | $1848.59 | $5.33 | x |
| 2014-12-31 | $1066.85 | $5.33 | x |
| 2015-12-31 | $355.37 | $5.33 | x |
| 2016-12-31 | $189.15 | $5.33 | x |
| 2017-12-31 | $106.77 | $5.33 | x |
| 2018-12-31 | $31.77 | $5.33 | x |
| 2019-12-31 | $23.22 | $5.33 | x |
| 2020-12-31 | $36.04 | $5.33 | x |
| 2021-12-31 | $17.72 | $5.33 | x |
| 2022-12-31 | $13.97 | $5.33 | x |
| 2023-12-31 | $10.83 | $5.33 | x |
| 2024-12-31 | $8.52 | $5.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atossa Genetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-35.68%) is above the historical average (-133.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -387.77% | 0.00% | 0.00x | 2.70x | $-126.03K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2011 | -220.70% | -229484.60% | 0.00x | 1.97x | $-3.60 Million |
| 2012 | -98.15% | -1054.26% | 0.07x | 1.32x | $-5.60 Million |
| 2013 | -101.73% | -1704.94% | 0.05x | 1.13x | $-11.84 Million |
| 2014 | -154.32% | -36518.83% | 0.00x | 1.24x | $-15.61 Million |
| 2015 | -421.20% | -896491.64% | 0.00x | 1.67x | $-16.13 Million |
| 2016 | -205.64% | 0.00% | 0.00x | 1.34x | $-6.68 Million |
| 2017 | -117.06% | 0.00% | 0.00x | 1.18x | $-8.82 Million |
| 2018 | -129.53% | 0.00% | 0.00x | 1.33x | $-12.29 Million |
| 2019 | -131.04% | 0.00% | 0.00x | 1.10x | $-18.56 Million |
| 2020 | -65.62% | 0.00% | 0.00x | 1.58x | $-20.54 Million |
| 2021 | -14.92% | 0.00% | 0.00x | 1.02x | $-34.42 Million |
| 2022 | -22.23% | 0.00% | 0.00x | 1.05x | $-38.03 Million |
| 2023 | -33.06% | 0.00% | 0.00x | 1.06x | $-39.20 Million |
| 2024 | -35.68% | 0.00% | 0.00x | 1.07x | $-32.65 Million |
Industry Comparison
This section compares Atossa Genetics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atossa Genetics Inc (ATOS) | $49.79 Million | -387.77% | 0.17x | $35.74 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more